Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC).
Barnett E, Schonhoft J, Schultz N, Lee J, Zaidi S, Abida W, Carmichael T, Dago A, Solit D, Wenstrup R, Scher H. Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC). Journal Of Clinical Oncology 2020, 38: 5531-5531. DOI: 10.1200/jco.2020.38.15_suppl.5531.Peer-Reviewed Original ResearchPoly ADP-ribose polymerase inhibitorsCirculating Tumor CellsCopy number variantsCastration-resistant prostate cancerCell-free DNACirculating tumor cell samplingInter-cellular heterogeneityDNA damage repairBRCA2 lossSource of genetic informationTumor cellsPoly ADP-ribose polymerase inhibitors therapyCopy number lossSource of tumor materialProstate cancer tissue specimensDetect circulating tumor cellsDNA damage repair deficiencyCTC-positive casesMetastatic CRPC patientsPre-treatment biopsiesCirculating tumor cell analysisGenome sequenceGenomic studiesCancer tissue specimensSequencing tissue
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply